Biomarker Panel for Cachexia Diagnosis via Metabolome Phase Portrait
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays lack the ability to rapidly and reliably distinguish between bacterial and viral infections, leading to unnecessary antibiotic use and the development of bacterial resistance, and fail to provide comprehensive information on biomarker profile changes during disease progression, particularly for cachexia and related catabolic diseases.
Innovation Solution
The development of a method to measure a plurality of biomarkers from a biological sample, generating a standard metabolome phase portrait that allows for the identification of disease progression, differentiation between bacterial and viral infections, and characterization of disease states by analyzing changes in biomarker levels over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current assays are used to diagnose infections, then disease state assessment is performed, but the ability to rapidly and reliably distinguish between bacterial and viral infections is lacking, leading to unnecessary antibiotic use
Solution Approach 1:
The patent segments the complex diagnostic process into distinct biomarker measurements (e.g., procalcitonin for bacterial infection, specific cytokines for viral infection) rather than using a single assay. This segmentation allows simultaneous assessment of multiple infection types through parallel measurement of different biomarkers, improving both speed and accuracy.
Solution Approach 2:
The patent utilizes changes in biomarker parameters (concentrations, ratios, temporal dynamics) to differentiate between bacterial and viral infections. By monitoring multiple parameters simultaneously and analyzing their patterns of change over time, the system achieves rapid and reliable infection type differentiation without requiring sequential testing.
2Loss of information
If comprehensive biomarker profiling is performed to understand disease progression, then detailed disease state information is obtained, but the complexity of analyzing vast numbers of potential biomarkers overwhelms rapid determination of disease state
Solution Approach 1:
The patent extracts and focuses on a specific subset of biomarkers that are most relevant to cachexia and catabolic disease progression, rather than analyzing all possible biomarkers. By selecting and measuring only the most informative biomarkers (e.g., specific amino acids, metabolites, inflammatory markers), the system maintains comprehensive disease information while reducing analytical complexity.
Solution Approach 2:
The patent employs preliminary bioinformatics analysis and pathway modeling to identify which biomarkers are most indicative of specific disease states and progression stages. This preliminary sorting and prioritization of biomarkers based on their informational value allows the system to focus resources on measuring and analyzing only the most relevant parameters, reducing overall complexity while maintaining information completeness.
3Reliability
If extensive biomarker measurement is used to characterize disease states, then comprehensive disease understanding is achieved, but pharmaceutical research and development expenditures increase unsustainably
Solution Approach 1:
The patent applies partial action by measuring a carefully selected subset of biomarkers that provides sufficient information for reliable disease state characterization without requiring exhaustive measurement of all possible biomarkers. This selective approach achieves robust disease understanding while controlling costs by avoiding unnecessary measurements.
Solution Approach 2:
The patent develops a multi-functional biomarker panel where the same set of biomarkers can characterize multiple aspects of disease state (diagnosis, progression stage, severity, response to treatment). This universality allows a single measurement set to serve multiple diagnostic and monitoring functions, reducing the total number of measurements needed while maintaining comprehensive disease characterization.
Data Source
AI summary
The invention is methods and related kits for diagnosing a disease state of cachexia by measuring biomarker profiles from a biological sample. Rapid measurement of early onset or progression of the disease in a subject is determined by measuring biomarker levels from the subject and optionally comparing the biomarker levels to a standard biomarker profile or metabolome phase portrait for the disease. The biomarkers measured in the assay and related kit for cachexia progression include biomarkers selected from the group consisting of lactate, citrate, formate, acetoacetate, 3-hydroxy butrate, alanine, glutamine, glutamate, valine, isoleucine leucine, thrionine, lysine, arginine, tyrosine, phenyl alanine, histidine and tryptophan.